Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12624000424505
Ethics application status
Approved
Date submitted
13/03/2024
Date registered
8/04/2024
Date last updated
18/08/2024
Date data sharing statement initially provided
8/04/2024
Type of registration
Prospectively registered
Titles & IDs
Public title
Mushrooms and their potential health effect on blood cholesterol
Query!
Scientific title
Investigating the effects of mushrooms compared to non-starchy vegetables on low-density lipoprotein cholesterol (LDL-C) in adults with mild hypercholesterolaemia – a randomised controlled cross-over trial
Query!
Secondary ID [1]
311717
0
None
Query!
Universal Trial Number (UTN)
None
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Hypercholesterolemia
333194
0
Query!
Condition category
Condition code
Cardiovascular
329882
329882
0
0
Query!
Coronary heart disease
Query!
Cardiovascular
330012
330012
0
0
Query!
Other cardiovascular diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Mushroom intervention: 200 g of Agaricus bisporus white button mushrooms (raw weight) per day replacing 200 g of usual vegetable intake for 4 weeks.
Foods and supplements high in beta-glucan or other substances that may affect cholesterol levels will be excluded from the diet and replaced with suitable alternatives (e.g. oats at breakfast could be replaced with cereal flakes or pearl barley could be replaced by brown rice).
At the beginning of the mushroom intervention phase during a ~25 min in-person consultation with a research dietitian/nutritionist, either at the baseline or visit 3, the participant will be provided with tailored advice (based on their usual diet) about how to include the mushrooms into their usual diet. Participants will also be provided with an instruction manual including information about the study design, the diet protocol, purchasing of mushrooms, monitoring of compliance, foods to avoid and alternatives, cooking ideas, recipes and frequently asked questions.
Participants will be provided with a voucher to purchase mushrooms weekly from a local supermarket chain (Coles Supermarket, that have stores spread out across Adelaide). The instruction manual will include clear instructions of where and the type of mushrooms to purchase. Note, mushrooms sold at all Coles stores in Adelaide are supplied by one mushroom producer.
To assess compliance, participants will complete a daily log about their consumption of mushrooms and excluded foods. The information will also be logged via a weekly online survey.
A cross-over study design will be followed. Washout period in-between interventions will be two weeks.
Query!
Intervention code [1]
328180
0
Treatment: Other
Query!
Intervention code [2]
328251
0
Lifestyle
Query!
Comparator / control treatment
Control intervention: 200 g of non-starchy vegetables per day replacing 200 g of normal vegetable intake excluding mushrooms.
Foods and supplements high in beta-glucan or other substances that may affect cholesterol levels will be excluded from the diet and replaced with suitable alternatives (the same alternatives as for the mushroom intervention).
At the beginning of the control intervention phase during a ~25 min in-person consultation with a research dietitian/nutritionist, either at the baseline or visit 3, the participant will be provided with tailored advice (based on their usual diet) about how to include non-starchy vegetables into their usual diet. Participants will also be provided with an instruction manual including information about the study design, the diet protocol, purchasing of non-starchy vegetables including a list of vegetable options, monitoring of compliance, foods to avoid and alternatives, cooking ideas, recipes and frequently asked questions.
Participants will be provided with a voucher to purchase non-starchy vegetables weekly from a local supermarket chain (Coles Supermarket, that have stores spread out across Adelaide). The instruction manual will include clear instructions of where and the type of vegetables to purchase.
To assess compliance, participants will complete a daily log about their consumption of non-starch vegetables and excluded foods. The information will also be logged via a weekly online survey.
A cross-over study design will be followed. Washout period in-between interventions will be two weeks.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
337652
0
Low-density lipoprotein cholesterol (LDL-C)
Query!
Assessment method [1]
337652
0
Serum LDL-C using Beckman Coulter
Query!
Timepoint [1]
337652
0
Baseline and end of each intervention period: visits 1 (day 0), 2 (day 28±3, primary timepoint), 3 (day 42±3) and 4 (day 70±3, primary timepoint) post commencement of dietary intervention.
Query!
Secondary outcome [1]
432687
0
Total cholesterol
Query!
Assessment method [1]
432687
0
Serum total cholesterol using Beckman Coulter
Query!
Timepoint [1]
432687
0
Baseline and end of each intervention period: visits 1 (day 0), 2 (day 28±3), 3 (day 42±3) and 4 (day 70±3) post commencement of dietary intervention
Query!
Secondary outcome [2]
432688
0
High-density lipoprotein cholesterol (HDL-C)
Query!
Assessment method [2]
432688
0
Serum HDL-C using Beckman Coulter
Query!
Timepoint [2]
432688
0
Baseline and end of each intervention period: visits 1 (day 0), 2 (day 28±3), 3 (day 42±3) and 4 (day 70±3) post commencement of dietary intervention
Query!
Secondary outcome [3]
432689
0
Triglycerides
Query!
Assessment method [3]
432689
0
Serum triglycerides using Beckman Coulter
Query!
Timepoint [3]
432689
0
Baseline and end of each intervention period: visits 1 (day 0), 2 (day 28±3), 3 (day 42±3) and 4 (day 70±3) post commencement of dietary intervention
Query!
Secondary outcome [4]
432690
0
Non-HDL-C
Query!
Assessment method [4]
432690
0
Calculated from blood test: Non-HDL-C = total cholesterol – HDL-C
Query!
Timepoint [4]
432690
0
Baseline and end of each intervention period: visits 1 (day 0), 2 (day 28±3), 3 (day 42±3) and 4 (day 70±3) post commencement of dietary intervention
Query!
Secondary outcome [5]
432691
0
Total cholesterol : HDL-C ratio
Query!
Assessment method [5]
432691
0
Calculated from blood test: Total cholesterol : HDL-C ratio = Total cholesterol / HDL-C
Query!
Timepoint [5]
432691
0
Baseline and end of each intervention period: visits 1 (day 0), 2 (day 28±3), 3 (day 42±3) and 4 (day 70±3) post commencement of dietary intervention
Query!
Secondary outcome [6]
432692
0
Dietary intake
Query!
Assessment method [6]
432692
0
Automated self-administered 24-hour dietary assessment tool (ASA-24 Australia, version 2016)
Query!
Timepoint [6]
432692
0
Two 24-hour recalls will be completed before commencement of dietary intervention (day -7 - -1); end of 1st intervention phase (days 21-27 post commencement of dietary intervention); end of washout period (days 35-41 post commencement of dietary intervention); end of 2nd intervention phase (days 63-69 post commencement of dietary intervention)
Query!
Secondary outcome [7]
432693
0
Body mass index (BMI)
Query!
Assessment method [7]
432693
0
Calculated from weight measured by electronic scales and height measured by stadiometer: BMI = weight (kg) / height (m) x height (m)
Query!
Timepoint [7]
432693
0
Baseline and end of each intervention period: visits 1 (day 0), 2 (day 28±3), 3 (day 42±3) and 4 (day 70±3) post commencement of dietary intervention
Query!
Secondary outcome [8]
432694
0
Participant perceptions and experience of the mushroom intervention.
Query!
Assessment method [8]
432694
0
Questionnaire specifically designed for this study and delivered electronically.
Query!
Timepoint [8]
432694
0
End of mushroom intervention period: visits 2 (day 28±3 post commencement of dietary intervention), and 4 (day 70±3 post commencement of dietary intervention)
Query!
Secondary outcome [9]
432695
0
Safety outcome: vital signs (blood pressure, heart rate, respiratory rate, temperature)
Query!
Assessment method [9]
432695
0
Blood pressure and heart rate: automated blood pressure monitor
Temperature: thermometer
Respiratory rate: counting the number of times the chest rises in one minute.
Query!
Timepoint [9]
432695
0
Baseline and end of each intervention period: visits 1 (day 0), 2 (day 28±3), 3 (day 42±3) and 4 (day 70±3) post commencement of dietary intervention
Query!
Secondary outcome [10]
432696
0
Safety outcome: Adverse events
Query!
Assessment method [10]
432696
0
Daily wellness log, weekly online survey designed specifically for this study, reviewed at study visits in a non-leading way.
Adverse events from cultivated commercial mushrooms are uncommon and may include allergy symptoms ranging from oral allergy syndrome to severe anaphylaxis.
Adverse events (AE); serious adverse events (SAE), and suspected unexpected serious adverse reactions (SUSAR) will be monitored including assessment of severity and causality of these events.
Query!
Timepoint [10]
432696
0
Throughout the intervention with follow-up at each study visit: visits 2 (day 28±3), 3 (day 42±3) and 4 (day 70±3) post commencement of dietary intervention
Query!
Secondary outcome [11]
432697
0
Safety outcome: Concomitant medications
Query!
Assessment method [11]
432697
0
Daily medication checklist, weekly online survey designed specifically for this study, reviewed at study visits in a non-leading way.
Query!
Timepoint [11]
432697
0
Throughout the intervention with follow-up at each study visit: visits 2 (day 28±3), 3 (day 42±3) and 4 (day 70±3) post commencement of dietary intervention,
Query!
Eligibility
Key inclusion criteria
INCLUSION CRITERIA:
1. Willing and able to provide written Informed Consent
2. Access to a personal email inbox
3. Male or Female individuals
4. Aged > or equal to 18 & <66 years of age at clinic screening
5. BMI > or equal to 18.5 kg/m2 and <35 kg/m2 at time of clinic screening
6. Low cardiovascular disease (CVD) risk score in individuals aged > or equal to 45 years of <5% estimated 5-year CVD risk determined using the Australian CVD risk calculator (cvdcheck.org.au)
7. Fasting LDL-cholesterol > or equal to 3.0 mmol/L and < or equal to 5 mmol/L confirmed at clinic screening (plasma)
8. Have access to a Coles supermarket
9. Ability to refrigerate mushrooms/vegetables and have the facilities to prepare and cook them
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
EXCLUSION CRITERIA:
1. Use of and not prepared to abstain from marine and algae derived omega-3 supplements at high dose (>900 mg/day of docosahexaenoic acid (DHA) / eicosapentaenoic acid (EPA)) or marine and algae derived omega 3 fortified foods that may, in the opinion of the PI or designee, affect lipid concentrations, within the 84 days of Day 0
2. Use of lipid lowering medications (e.g. statins, metformin, fibrates, cholesterol absorption inhibitors, nicotinic acid) or lipid raising medications (eg. Beta blockers, steroids, amiodarone, diuretics) within 28 days of Day 0.
3. Use of and not prepared to abstain from supplements, or foods containing ß-glucan (oats, barley, rye, nutritional yeast, mushrooms other than study mushrooms) or other substances (e.g. psyllium, plant sterol fortified foods and supplements, curcumin, turmeric) that may, in the opinion of the PI or designee, affect lipid concentrations within 14 days of Day 0
4. Previous diagnosis of chronic disease such as CVD, diabetes
(Type I, Type II, and/or Gestational Diabetes), cancer, familial hypercholesterolaemia, kidney disease, liver disease
5. Smoking (i.e., history of smoking within the last six months)
6. Serum triglycerides >4.5mmol/L (LDL-cholesterol concentrations are unreliable in the presence of high triglyceride levels) confirmed at clinic screening (using capillary plasma)
7. Hypertension (blood pressure > or equal to 140/90mmHg)
8. Suspected aversion and/or intolerance to mushrooms
9. Unwilling or unable to maintain usual levels of physical activity or dietary intake for the duration of the study
10. Currently pregnant and/or nursing (lactating), self-reported by the applicant
11. Currently hospitalised or any planned hospitalisations during the study that may affect the applicant’s ability to comply with the study in the opinion of the PI or designee
12. Received an investigational drug within 90 days of Day 0, that in the opinion of the PI or designee may affect the outcome of the study
13. Unable to comply, experience distress with study procedures, or has a medical condition and/or receiving medical treatments (including medications) that in the opinion of the PI or designee, may affect the outcome of the study
14. Travel which may interfere with complying to the study diet guidelines
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software.
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
A sample size of 42 participants will provide 80% statistical power at a=0.05 (two-tailed) and account for a dropout rate of 20%, to detect an LDL-C effect size of ~0.25 mmol/L,
Prior to database lock, a final detailed Statistical Analysis Plan (SAP) will be available.
In brief, statistical analysis will be performed using SPSS software. Comparisons between interventions for continues outcome variables will be analysed using linear mixed models for repeated measures. In cases where significant intervention x time interactions are observed post-hoc analyses with Bonferroni adjustments will be conducted. The data will be examined for interaction effects due to the order in which the meals were consumed. A p-value <0.05 will be considered significant.
Query!
Recruitment
Recruitment status
Withdrawn
Query!
Reason for early stopping/withdrawal
Lack of funding/staff/facilities
Query!
Date of first participant enrolment
Anticipated
8/04/2024
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
30/08/2024
Query!
Actual
Query!
Date of last data collection
Anticipated
29/11/2024
Query!
Actual
Query!
Sample size
Target
42
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Recruitment hospital [1]
26265
0
CSIRO Nutrition & Health Research Clinic - Adelaide
Query!
Recruitment postcode(s) [1]
42234
0
5000 - Adelaide
Query!
Funding & Sponsors
Funding source category [1]
316045
0
Commercial sector/Industry
Query!
Name [1]
316045
0
Horticultural Innovation
Query!
Address [1]
316045
0
Query!
Country [1]
316045
0
Australia
Query!
Primary sponsor type
Government body
Query!
Name
Commonwealth Scientific and Industrial Research Organisation (CSIRO)
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
318318
0
None
Query!
Name [1]
318318
0
Query!
Address [1]
318318
0
Query!
Country [1]
318318
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
314867
0
CSIRO Health and Medical Human Research Ethics Committee
Query!
Ethics committee address [1]
314867
0
https://www.csiro.au/en/about/Policies/Ethical-human-research
Query!
Ethics committee country [1]
314867
0
Australia
Query!
Date submitted for ethics approval [1]
314867
0
14/11/2023
Query!
Approval date [1]
314867
0
05/02/2024
Query!
Ethics approval number [1]
314867
0
2023_068_HREC
Query!
Summary
Brief summary
Reducing blood cholesterol is one of the key strategies to reduce cardiovascular disease risk (CVD), the leading cause of mortality worldwide. While the evidence for the cholesterol lowering effects of ß-glucan from oats and barley are well established, there is less evidence for ß-glucan from other dietary sources such as fungi, yeast and algae. The aim of the current study is to investigate the effects of consuming 200 g/day of white button mushrooms (Agaricus bisporus) (raw weight) on serum LDL-cholesterol in adults with mild hypercholesterolaemia compared to 200 g/day non-starchy vegetables over four weeks.
Query!
Trial website
The trial website is still under development
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
132986
0
Prof Welma Stonehouse
Query!
Address
132986
0
CSIRO, South Australian Medical Research Institute Building, North Terrace, Adelaide SA 5000
Query!
Country
132986
0
Australia
Query!
Phone
132986
0
+61 08 83038919
Query!
Fax
132986
0
Query!
Email
132986
0
[email protected]
Query!
Contact person for public queries
Name
132987
0
Brooke Wymond
Query!
Address
132987
0
CSIRO, South Australian Medical Research Institute Building, North Terrace, Adelaide SA 5000
Query!
Country
132987
0
Australia
Query!
Phone
132987
0
+61 08 83038856
Query!
Fax
132987
0
Query!
Email
132987
0
[email protected]
Query!
Contact person for scientific queries
Name
132988
0
Welma Stonehouse
Query!
Address
132988
0
CSIRO, South Australian Medical Research Institute Building, North Terrace, Adelaide SA 5000
Query!
Country
132988
0
Australia
Query!
Phone
132988
0
+61 08 83038919
Query!
Fax
132988
0
Query!
Email
132988
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
All of the individual participant data collected during the trial, after de-identification.
Query!
When will data be available (start and end dates)?
Following publication, no end date
Query!
Available to whom?
Researchers who request access to the data and provide a proposal with sound rationale and methodology and pending Principal Investigator and Human Research Ethics Committee approval.
Query!
Available for what types of analyses?
Any purpose.
Query!
How or where can data be obtained?
CSIRO Data Access Portal (DAP) - access is subject to CSIRO and Human Research Ethics Commitee approval. Access to the portal may be requested by emailing the principal investigator (
[email protected]
).
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Doc. No.
Type
Citation
Link
Email
Other Details
Attachment
21854
Analytic code
[email protected]
21855
Data dictionary
[email protected]
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF